Possible Mechanisms of Acquired Resistance to Anti-angiogenic Drugs: Implications for the Use of Combination Therapy Approaches

Author： Kerbel R.S.  

Publisher： Springer Publishing Company

ISSN： 0167-7659

Source： Cancer and Metastasis Reviews, Vol.20, Iss.1-2, 2001-03, pp. : 81-88

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Anti-angiogenic therapy for osteosarcoma

By Quan Gerald  

Cancer and Metastasis Reviews, Vol. 25, Iss. 4, 2006-12 ,pp. : 707-713

Springer Publishing Company

Access to resources Recommend Favorite

Anti-angiogenic Therapy in Pediatric Neuro-oncology

By Kieran Mark  

Journal of Neuro-Oncology, Vol. 75, Iss. 3, 2005-12 ,pp. : 327-334

Springer Publishing Company

Access to resources Recommend Favorite

Anti-Angiogenic Therapy as a Cancer Treatment Paradigm

By  

Current Medicinal Chemistry - Anti-Cancer Agents, Vol. 5, Iss. 2, 2005-03 ,pp. : 115-130

Bentham Science Publishers

Access to resources Recommend Favorite

Anti-Angiogenic Therapy in Renal Cell Carcinoma

By  

Recent Patents on Anti-Cancer Drug Discovery, Vol. 5, Iss. 1, 2010-01 ,pp. : 77-83

Bentham Science Publishers

Access to resources Recommend Favorite

Combined therapy of temozolomide and ZD6474 (vandetanib) effectively reduces glioblastoma tumor volume through anti-angiogenic and anti-proliferative mechanisms

By                

Molecular Medicine Reports, Vol. 6, Iss. 1, 2012-01 ,pp. : 88-92

Spandidos Publications

Access to resources Recommend Favorite